MERCK KGAA O.N./ DE0006599905 /
2024-04-25 8:01:12 AM | Chg. -0.15 | Volume | Bid8:32:51 AM | Ask8:32:51 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
152.50EUR | -0.10% | 0 Turnover: 0.00 |
151.70Bid Size: 100 | 152.55Ask Size: 100 | 19.95 bill.EUR | 1.43% | 23.78 |
GlobeNewswire
04-24
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
04-24
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investiga...
GlobeNewswire
04-24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ...
GlobeNewswire
04-24
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASC...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA